FDA Questions Kennedy-Backed Peptides Ahead of Advisory Panel Review

AI Summary

FDA staff raised concerns about peptides supported by Kennedy before an upcoming advisory panel review. Specific issues related to the safety and efficacy of these peptides were highlighted, which may affect their approval process. This review is significant as it could influence investor sentiment regarding biotech stocks tied to Kennedy's ventures. Outcomes from FDA advisory panels often lead to notable market reactions for associated firms. The potential ramifications could impact future research and funding for peptide-based therapies.